Healthcare & Medical Devices Global On demand · 24-48h

Global Allergy Point-of-Care Testing Market Strategic Research Report

Global Allergy Point-of-Care Testing Market Strategic Resear…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Allergy Point-of-Care Testing Market
$1.22B2025
10.9%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Lateral Flow, Fluorescent Immunoassay, Microarray Assay

By Application: Primary Care, Pediatric Clinic, Hospital Lab, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Thermo Fisher Scientific, Abbott, Roche, Siemens Healthineers, bioMérieux, Quidel, Hycor Biomedical, EUROIMMUN Medizinische, Phadia, Stallergenes Greer

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 95 pages
Market size 2025
$1.22B
Billion USD
Forecast CAGR
10.9%
2025-2032
Forecast 2032
$2.5B
Projected
Regiões
5
Asia Pacific · Latin America · MEA · Europe · North America

Visão geral

Scope of the Report

The global Allergy Point-of-Care Testing market size is predicted to grow from US$ 1,220 million in 2025 to US$ 2,520 million in 2032; it is expected to grow at a CAGR of 10.9% from 2026 to 2032.

Allergy Point-of-Care Testing refers to portable, rapid diagnostic technologies used in clinical or primary care settings to provide real-time assessment of immune responses triggered by specific allergens. These tests typically utilize immunochromatography, antigen-antibody binding assays, or microarray platforms to rapidly measure specific immunoglobulin E (IgE) levels or related inflammatory biomarkers in samples such as blood, saliva, or skin. They enable quick screening and identification of common allergies, including food allergies, seasonal allergies, pet allergies, and drug allergies. Compared with conventional laboratory testing, point-of-care allergy tests are characterized by ease of use, rapid results, minimal preprocessing, and the ability to perform tests at the bedside. This supports enhanced primary care capacity, optimized clinical workflows, and improved patient engagement in allergy management.The average gross profit margin of this product is 67%.

The global prevalence of allergic diseases continues to rise, particularly due to urbanization and increasing environmental pollution, resulting in rapidly growing demand for allergy diagnostics. Traditional laboratory testing is limited by time requirements and lack of proximate service capacity, whereas point-of-care testing offers rapid turnaround and broader coverage for primary care settings. The proliferation of telemedicine, mobile health platforms, and smart devices supports connectivity and remote interpretation of allergy POC data. Meanwhile, growing patient health awareness drives demand for rapid diagnostic feedback and engagement in self-management, leading to wider acceptance of point-of-care solutions in pediatrics, respiratory care, and home health monitoring. Furthermore, national public health policies increasingly include chronic immune and allergic conditions in prevention and control priorities, bolstering primary care capabilities and driving demand for diagnostic tools.

The adoption of allergy point-of-care testing faces challenges in diagnostic accuracy and standardization, as methodological differences across platforms can lead to inconsistent results, undermining clinical confidence. The broad spectrum of allergens and significant individual variability make comprehensive coverage difficult with single-metric assays, posing risks of under- or misdiagnosis. Regulatory frameworks differ widely across regions for POC products, and lack of unified quality control and clinical validation standards raises compliance risks. Market competition between low-end lateral-flow products and high-end fluorescence or microarray platforms, with significant differences in pricing and service capabilities, may dampen adoption of higher-value solutions.

Primary care facilities and chronic disease management centers are increasingly adopting allergy POC products, particularly in community clinics, pediatric wellness, and elderly health services. Patient and household demand for portable, easy-to-use, non-technical self-testing devices continues to grow, driving market penetration of home testing solutions. Clinical end-users increasingly prefer high-sensitivity and high-specificity platforms, especially for complex allergy management, food allergy subtyping, and personalized care guidance. Integration of point-of-care data with digital health ecosystems and chronic care platforms is becoming mainstream, providing unified diagnostic, consultative, and longitudinal health record capabilities.

The upstream supply chain for allergy point-of-care testing primarily includes immune recognition elements (e.g., specific antigens/antibodies), test substrates (e.g., high-affinity membranes, microarray chip bases), signal amplification and detection components (e.g., fluorescent labels, gold nanoparticles, optical/electrochemical sensor elements), and disposable sample collection and processing consumables. High-quality antigen and antibody materials require precise protein expression, purification processes, and stringent activity validation, forming the core basis for assay sensitivity and specificity. Substrate materials must have stable binding capacity and low background signal characteristics, directly influencing signal-to-noise and reproducibility. Performance of signal detection components impacts quantitative accuracy and user experience, posing high demands on integration and cost control. With the rise of green manufacturing and sustainable materials initiatives, the upstream supply chain is also moving toward environmentally friendly, recyclable materials and packaging optimization.

This report presents a comprehensive overview of the global Allergy Point-of-Care Testing market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Lateral Flow
  • Fluorescent Immunoassay
  • Microarray Assay

Segment by Allergen Category

  • Food Allergy
  • Respiratory Allergy
  • Drug Allergy
  • Contact Allergy

Segment by Product Type

  • Rapid Specific-IgE Kits
  • Skin-Prick Testing Kits
  • Rapid Anaphylaxis Kits
  • Sample Collection Devices

Segment by Application

  • Primary Care
  • Pediatric Clinic
  • Hospital Lab
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Allergy Point-of-Care Testing market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Primary Care, Pediatric Clinic, Hospital Lab evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Allergy Point-of-Care Testing Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 10.9%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.22B
2025
Forecast
$2.5B
2032
CAGR
10.9%
2025–2032
Regiões
5
global
Key companies
Thermo Fisher ScientificAbbottRocheSiemens HealthineersbioMérieuxQuidelHycor BiomedicalEUROIMMUN Medizinische
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Lateral FlowFluorescent ImmunoassayMicroarray Assay
By Application
Primary CarePediatric ClinicHospital LabOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Lateral Flow
  • 3.1.3 Fluorescent Immunoassay
  • 3.1.4 Microarray Assay
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Primary Care
  • 4.1.3 Pediatric Clinic
  • 4.1.4 Hospital Lab
  • 4.1.5 Other
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Thermo Fisher Scientific
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Abbott
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Roche
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Siemens Healthineers
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 bioMérieux
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Quidel
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Hycor Biomedical
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 EUROIMMUN Medizinische
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Phadia
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Stallergenes Greer
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Allergy Point-of-Care Testing market?
The global Allergy Point-of-Care Testing market is estimated at US$ 1.22 billion in 2025 (base year) and is projected to reach US$ 2.52 billion by 2032.
How fast is the Allergy Point-of-Care Testing market expected to grow?
The market is expected to grow at a CAGR of 10.9% from 2026 to 2032, expanding from US$ 1.22 billion in 2025 to US$ 2.52 billion in 2032, roughly 2.1 times its base-year value.
What does the Allergy Point-of-Care Testing market cover?
Allergy Point-of-Care Testing refers to portable, rapid diagnostic technologies used in clinical or primary care settings to provide real-time assessment of immune responses triggered by specific allergens. These tests typically utilize immunochromatography, antigen-antibody binding assays, or microarray platforms to rapidly measure specific immunoglobulin E (IgE) levels or related inflammatory biomarkers in samples such as blood, saliva, or skin.
How is the Allergy Point-of-Care Testing market segmented by type?
By type, the market is segmented into Lateral Flow, Fluorescent Immunoassay and Microarray Assay.
What are the key applications of Allergy Point-of-Care Testing?
Key applications covered include Primary Care, Pediatric Clinic, Hospital Lab and Other.
Which companies are profiled in the Allergy Point-of-Care Testing market report?
Key players profiled include Thermo Fisher Scientific, Abbott, Roche, Siemens Healthineers, bioMérieux, Quidel, Hycor Biomedical and EUROIMMUN Medizinische, among 10 companies covered in total.
What geographies does the Allergy Point-of-Care Testing market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Allergy Point-of-Care Testing?
Meanwhile, growing patient health awareness drives demand for rapid diagnostic feedback and engagement in self-management, leading to wider acceptance of point-of-care solutions in pediatrics, respiratory care, and home health monitoring.
What are the main risks and barriers in the Allergy Point-of-Care Testing market?
The adoption of allergy point-of-care testing faces challenges in diagnostic accuracy and standardization, as methodological differences across platforms can lead to inconsistent results, undermining clinical confidence.
Who should buy the Allergy Point-of-Care Testing market report?
The report is intended for manufacturers and solution providers, distributors and end users in Primary Care, Pediatric Clinic and Hospital Lab, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Allergy Point-of-Care Testing market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from US$ 3.500,00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.